‘Peptide receptor radionuclide therapy in the management of advanced pheochromocytoma and paraganglioma: A systematic review and meta‐analysis’
@article{Satapathy2019PeptideRR, title={‘Peptide receptor radionuclide therapy in the management of advanced pheochromocytoma and paraganglioma: A systematic review and meta‐analysis’}, author={Swayamjeet Satapathy and B. Mittal and A. Bhansali}, journal={Clinical Endocrinology}, year={2019}, volume={91}, pages={718 - 727} }
Inoperable and metastatic pheochromocytomas and paragangliomas (PPGLs) present a therapeutic challenge with current treatment options being limited to radiolabelled meta‐iodo‐benzyl‐guanidine (MIBG) and systemic chemotherapy. Peptide receptor radionuclide therapy (PRRT) seems to be a promising option for these patients with few studies reporting favourable response. This systematic review was conducted to evaluate the efficacy and safety of PRRT in patients with advanced PPGLs.
Topics from this paper
8 Citations
177Lu-DOTATATE therapy in metastatic/inoperable pheochromocytoma-paraganglioma
- Medicine
- Endocrine connections
- 2020
- PDF
131I-metaiodobenzylguanidine and peptide receptor radionuclide therapy in pheochromocytoma and paraganglioma
- Medicine
- Current opinion in oncology
- 2020
Emerging Treatments for Advanced/Metastatic Pheochromocytoma and Paraganglioma
- Medicine
- Current Treatment Options in Oncology
- 2020
- PDF
131I-MIBG negative progressive symptomatic metastatic paraganglioma: response and outcome with 177Lu-DOTATATE peptide receptor radionuclide therapy
- Medicine
- Annals of Nuclear Medicine
- 2020
Case Report: Primary Hypothyroidism Associated With Lutetium 177-DOTATATE Therapy for Metastatic Paraganglioma
- Frontiers in Endocrinology
- 2020
Genetics, diagnosis, management and future directions of research of phaeochromocytoma and paraganglioma: a position statement and consensus of the Working Group on endocrine hypertension of the European society of hypertension.
- Medicine
- Journal of hypertension
- 2020
- 7
The difficulties in the diagnosis and treatment of malignant paraganglioma of the urinary bladder.
- Medicine
- Endokrynologia Polska
- 2020
References
SHOWING 1-10 OF 43 REFERENCES
Peptide Receptor Radionuclide Treatment and (131)I‐MIBG in the management of patients with metastatic/progressive phaeochromocytomas and paragangliomas
- Medicine
- Journal of surgical oncology
- 2017
- 30
- PDF
131I‐MIBG therapy for malignant paraganglioma and phaeochromocytoma: systematic review and meta‐analysis
- Medicine
- Clinical endocrinology
- 2014
- 77
Chemotherapy with cyclophosphamide, vincristine and dacarbazine for malignant paraganglioma and pheochromocytoma: systematic review and meta‐analysis
- Medicine
- Clinical endocrinology
- 2014
- 76
Efficacy of Peptide Receptor Radionuclide Therapy for Functional Metastatic Paraganglioma and Pheochromocytoma
- Medicine
- The Journal of clinical endocrinology and metabolism
- 2017
- 55
- PDF
Clinical benefits of systemic chemotherapy for patients with metastatic pheochromocytomas or sympathetic extra‐adrenal paragangliomas
- Medicine
- Cancer
- 2012
- 90
Treatment of inoperable or metastatic paragangliomas and pheochromocytomas with peptide receptor radionuclide therapy using 177Lu-DOTATATE.
- Medicine
- European journal of endocrinology
- 2019
- 4
- PDF
Recent advances in the management of malignant pheochromocytoma and paraganglioma: focus on tyrosine kinase and hypoxia-inducible factor inhibitors
- Medicine
- F1000Research
- 2018
- 15
- PDF
Peptide Receptor Radionuclide Therapy and the Treatment of Gastroentero-pancreatic Neuroendocrine Tumors: Current Findings and Future Perspectives
- Medicine
- Nuclear Medicine and Molecular Imaging
- 2018
- 14